XOSPATA 40 mg (Gilteritinib) Tablet is a powerful antineoplastic inhibitor of the receptor tyrosine kinases (RTKs), FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11), and anaplastic lymphoma kinase (ALK or CD246). Gilteritinib binds to and inhibits FLT3, AXL, and ALK in wild-type and mutant versions. This may disrupt the signal transduction pathways mediated by FLT3, AXL, and ALK, reducing tumor cell growth in cancer cell types that overexpress these RTKs. Gilteritinib is used to treat acute myeloid leukemia (AML) with FLT3 mutations.
FLT3, AXL, and ALK are overexpressed or mutated in various cancer cell types. They play an essential role in tumor cell proliferation and survival.
Take this medicine by mouth once a day, with or without food, as instructed by your doctor. Completely swallow the tablets. The dosage is determined by your medical condition and treatment response.